Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

76.59
-0.0100-0.01%
Post-market: 76.590.00000.00%18:01 EDT
Volume:2.06M
Turnover:157.22M
Market Cap:15.00B
PE:-21.46
High:77.24
Open:76.20
Low:75.02
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:1.42
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.96
PE(LYR):-20.24

Loading ...

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
2 hours ago

BridgeBio Signs Voluntary Access and Affordability Agreement with US Government

Reuters
·
2 hours ago

BridgeBio Pharma, - to Offer Attruby Via Medicare Part D Without Future Pricing Mandates

THOMSON REUTERS
·
2 hours ago

BridgeBio Pharma - to Expand State Medicaid Access to Marketed Medicine Via Generous Model

THOMSON REUTERS
·
2 hours ago

BridgeBio Pharma, - Agreement Does not Impact Forgingbridges Copay Assistance Program

THOMSON REUTERS
·
2 hours ago

BridgeBio Pharma - Does not Expect Future Pricing Mandates; Terms Remain Confidential

THOMSON REUTERS
·
2 hours ago

BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

THOMSON REUTERS
·
2 hours ago

BridgeBio Publishes Discover-ATTR Digital Registry Presentation on ATTR-CM Data Integration

Reuters
·
Yesterday

BridgeBio Pharma Currently Down Eight Consecutive Days, on Pace for Record Losing Streak

Dow Jones
·
Yesterday

Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)

TIPRANKS
·
Yesterday

BridgeBio Pharma presents new analyses from Phase 3 ATTRibute-CM study

TIPRANKS
·
Yesterday

BridgeBio Pharma Doses First Patient in Trial Evaluating Long-Term Impact of Heart Disease Medicine

MT Newswires Live
·
Aug 26

BridgeBio Pharma doses first patient in ASCEND-ATTR trial

TIPRANKS
·
Aug 26

BridgeBio Announces First Participant Dosed in Ascend-Attr, a Phase 3B/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in Attr-Cm

THOMSON REUTERS
·
Aug 26

13D Filings

Dow Jones
·
Aug 22

BridgeBio Pharma CEO Neil Kumar Disposes of USD 3.07 Million in Common Shares

Reuters
·
Aug 21

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

MT Newswires Live
·
Aug 14

Analysts Are Bullish on Top Healthcare Stocks: BridgeBio Pharma (BBIO), Pyxis Oncology (PYXS)

TIPRANKS
·
Aug 14

BridgeBio Pharma, - Announces Pricing of 5,000,000 Share Secondary Offering by KKR Genetic Disorder L.p.

THOMSON REUTERS
·
Aug 14

BridgeBio Launches Secondary Offering of 5,000,000 Shares by KKR Genetic Disorder LP

Reuters
·
Aug 14